MediSix Therapeutics, Inc.
BOSTON, MA · Founded 2019 · CIK 0001790058 · Biotech · Acquired
PEBL (Protein Expression BLocker), a technology to enhance CAR T-cell therapy efficacy for T-cell malignancies
medisixtx.com →- Grants
- —
- No SBIR or STTR on record
- Sector median: 1
- Raised
- $35M
- 2 Form D · Apr 2021
- 66 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 11
- 0 granted · 11 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201920202021
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $20,358,686 | |
| Private capital raised | Form D · SEC | $15,000,000 |
Form D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1170 | KODIAK BP, LLC | — | $13M |
| 1171 | Nova Mentis Life Science Corp. | — | $188K |
| 1172 | SCYNEXIS, INC. | — | $5.5M |
| 1173 | MediSix Therapeutics, Inc. | — | $35M |
| 1174 | ISOThrive Inc. | — | $17M |
| 1175 | Unleash Immuno Oncolytics, Inc. | — | $3.0M |
| 1176 | Cessation Therapeutics, Inc. | — | $6.8M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Andrew BruceDirector · Executive Officer
- Michael CarusiDirector
- William HarringtonDirector
- Sarah LimExecutive Officer
- Kenneth NoonanDirector · Executive Officer
- George PosteDirector
Patents
- Engineered Immune Cells Expressing A Car And A Plurality Of Protein Expression Blockers And Uses Thereofapplication
- Blockade Of CD3 Expression And Chimeric Antigen Receptors For Immunotherapyapplication
- Methods And Systems For Production Of Engineered T-cellsapplication
- Engineered Immune Cells Expressing A Car And A Plurality Of Protein Expression Blockers And Uses Thereofapplication
- Blockade Of CD3 Expression And Chimeric Antigen Receptors For Immunotherapyapplication
- Engineered Immune Cells Expressing A Car And A Plurality Of Protein Expression Blockers And Uses Thereofapplication
- Methods And Systems For Production Of Engineered T-cellsapplication
- Blockade Of CD3 Expression And Chimeric Antigen Receptors For Immunotherapyapplication
- Engineered Immune Cells Expressing A Car And A Plurality Of Protein Expression Blockers And Uses Thereofapplication
- Engineered Immune Cells Expressing A Car And A Plurality Of Protein Expression Blockers And Uses Thereofapplication
- Methods And Systems For Production Of Engineered T-cellsapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.